JP2019517508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517508A5 JP2019517508A5 JP2018563076A JP2018563076A JP2019517508A5 JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5 JP 2018563076 A JP2018563076 A JP 2018563076A JP 2018563076 A JP2018563076 A JP 2018563076A JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- cell receptor
- medicine
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims 62
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 53
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 108091008874 T cell receptors Proteins 0.000 claims 50
- 239000003814 drug Substances 0.000 claims 45
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 33
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 33
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 31
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims 28
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 14
- 230000001747 exhibiting effect Effects 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 238000002255 vaccination Methods 0.000 claims 6
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101710204040 Myosin-3 Proteins 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022132995A JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760.7 | 2016-06-02 | ||
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Division JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517508A JP2019517508A (ja) | 2019-06-24 |
| JP2019517508A5 true JP2019517508A5 (enExample) | 2020-07-16 |
| JP7321709B2 JP7321709B2 (ja) | 2023-08-07 |
Family
ID=56132759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563076A Active JP7321709B2 (ja) | 2016-06-02 | 2017-06-02 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (enExample) |
| EP (2) | EP4253419A3 (enExample) |
| JP (2) | JP7321709B2 (enExample) |
| AU (1) | AU2017275782B2 (enExample) |
| CA (1) | CA3026172A1 (enExample) |
| DK (1) | DK3463436T3 (enExample) |
| ES (1) | ES2965957T3 (enExample) |
| FI (1) | FI3463436T3 (enExample) |
| HR (1) | HRP20231650T1 (enExample) |
| HU (1) | HUE065176T2 (enExample) |
| LT (1) | LT3463436T (enExample) |
| PL (1) | PL3463436T3 (enExample) |
| PT (1) | PT3463436T (enExample) |
| RS (1) | RS65007B1 (enExample) |
| SI (1) | SI3463436T1 (enExample) |
| WO (1) | WO2017207814A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| EP3815711A4 (en) * | 2018-06-29 | 2022-08-10 | Taiho Pharmaceutical Co., Ltd. | ANTITUMOR AGENT AND ITS METHOD OF EVALUATION |
| JP2024522178A (ja) | 2021-06-09 | 2024-06-11 | ウルティモバックス アクチボラグ | コンジュゲート |
| WO2024083867A1 (en) * | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE353365T1 (de) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| PT1503794E (pt) | 2002-04-12 | 2012-06-21 | Medarex Inc | Métodos de tratamento usando anticorpos contra ctla-4 |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| HRP20170251T1 (hr) | 2010-03-15 | 2017-04-21 | Stichting Voor De Technische Wetenschappen | Peptidi, konjugati i postupak za povećanje imunogenosti cjepiva |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| AU2013308409A1 (en) | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| ES2739913T3 (es) * | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
| EA034110B1 (ru) | 2013-03-15 | 2019-12-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| BR112016014410A2 (pt) | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| EP3088614B1 (en) | 2013-12-27 | 2021-08-25 | Xiamen Solex High-Tech Industries Co., Ltd. | Flush-mounted pre-embedded assembly |
| SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| CA2946418C (en) | 2014-05-13 | 2023-07-04 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| EP3164157A4 (en) | 2014-07-01 | 2018-02-28 | Vicus Therapeutics, LLC | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| CA2954278A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| MX2017000836A (es) | 2014-07-18 | 2017-11-17 | Advaxis Inc | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| US20190282632A1 (en) | 2014-10-23 | 2019-09-19 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| WO2016073759A1 (en) | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Combination immunotherapy |
| WO2017125844A1 (en) | 2016-01-19 | 2017-07-27 | Pfizer Inc. | Cancer vaccines |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517508A5 (enExample) | ||
| AU2018250464B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| TWI796299B (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| JP2021100956A (ja) | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 | |
| TW202140068A (zh) | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| KR20160044035A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| Fisher et al. | Neoadjuvant anti-tumor vaccination prior to surgery enhances survival | |
| US9603912B2 (en) | Cancer therapy | |
| Nasonov et al. | The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA | |
| Parums | Status of immune therapy in non-small cell lung cancer (NSCLC) | |
| Myers et al. | Overcoming Cancer Tolerance with Immune Checkpoint Blockade | |
| RU2020117746A (ru) | Иммунотерапевтические способы лечения и/или профилактики рака легких |